

201705-Yervoy-PAC-EU-artwork-v01_4 clean.indd 1

10/07/2017 16.53.10



201705-Yervoy-PAC-EU-artwork-v01_4 clean.indd 2

10/07/2017 16.53.35

YERVOY® (ipilimumab)

This card has important information.

Always carry this card with you and show it to any doctor you may need to see (for example, if your regular doctor is unavailable or you are travelling).

Tell your Doctor right away if you have any of these symptoms or any other symptoms

BOWFL AND STOMACH1

- diarrhoea (watery, loose or soft stools), bloody or dark-coloured stools
- more frequent bowel movements than usual
- pain or tenderness in your stomach or abdominal area, nausea, vomiting

LIVFR1

- eye or skin yellowing (jaundice)
- pain on the right side of your stomach area
- dark urine

SKIN¹

- skin rash with or without itching, dry skin
- blisters and/or peeling of the skin, mouth sores
- swelling of the face or lymph glands

GENERAL1

- fever, headaches, tiredness
- bleeding
- behavioural changes (e.g. less sex drive, being irritable or forgetful)

NERVES1

- muscle weakness
- numbness or tingling in legs, arms, or face
- dizziness, loss of consciousness or difficulty waking up

EYE1

- redness in the eve
- pain in the eye
- vision problems or blurry vision

IMPORTANT INFORMATION

- Report any of these symptoms to your doctor right away
- Symptoms that may appear mild can quickly worsen if left untreated¹
 Don't try to treat these
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped, allowing you to get the maximum benefit from treatment.
- Signs and symptoms may be delayed and may occur weeks to months after your last injection¹
- Don't try to treat these symptoms yourself without consulting with your doctor first
- Carry this Patient Alert Card and show to any doctor you might interact with, and say that you are being treated with ipilimumab.

You can get more information on YERVOY® Package Leaflet: www.ema. europa.eu

My physician's contact information

Name of Physician
Office Phane
Office Phone
After-hours Phone
My Name and Phone
Name of Caregiver (in case of emergency)

IMPORTANT information for healthcare providers

- This patient is treated with YERVOY®, a drug used for the treatment of melanoma.
- Immune-related Adverse Reactions (irARs), can mostly occur during the induction period, but may appear months after the last dose of YERVOY®.
- Early diagnosis and appropriate management are essental to minimise life-threatening complicati ons. YERVOY® specific management guidelines for irARs are available.
- If you are a doctor not specialised in oncology, please contact a melanoma specialist.

Please consult YERVOY® Summary of Product Characteristics at www.ema.europa.eu or call Medical Information at 00 356 23976505 for more information.

1. YERVOY™ Package Leaflet

Bristol-Myers Squibb Company. All rights reserved. - V1.41EU/07JUL2017